We open different perspectives
to healthcare market players
Advising, projects & support for public and private health organizations
Company profile - 2015
What’s the real meaning of ‘success’?
• 22 of these 23 people
have something in
common: they didn’t
set up a company.
Although no one
denies that they were
great scientists…
• Only one of them,
Ernst Solvay,
estabished a
succesful business.
www.hittinnova.com
Seated (L-R): Walther Nernst, Marcel Brillouin, Ernest Solvay, Hendrik Lorentz, Emil Warburg, Jean Baptiste Perrin, Wilhelm
Wien, Marie Curie, and Henri Poincaré. Standing (L-R): Robert Goldschmidt, Max Planck, Heinrich Rubens, Arnold Sommerfeld,
Frederick Lindemann, Maurice de Broglie, Martin Knudsen, Friedrich Hasenöhrl, Georges Hostelet, Edouard Herzen, James
Hopwood Jeans, Ernest Rutherford, Heike Kamerlingh Onnes, Albert Einstein, and Paul Langevin.
Health Innovation Technology Transfer 1
Failure in BioTech is a constant
• If failure means liquidating all assets, with
investors losing most or all the money they
put into the company, then the failure rate for
start-ups is 30 to 40 percent
New business founded in 1992 still alive by year
• If failure refers to failing to see the projected
return on investment, then the failure rate is
70 to 80 percent
• If failure is defined as declaring a projection
and then falling short of meeting it, then the
failure rate is a whopping 90 to 95 percent
www.hittinnova.com
Illusions of Entrepreneurship: The Costly Myths that
Entrepreneurs, Investors, and Policy Makers Live
Scott Shane , Professor of Entrepreneurial Studies at Case
Western Reserve University
Health Innovation Technology Transfer 2
Successful ways always jump outside the box
•
Nowadays, independent and honest visions
are critical factors for success in the
innovation & technological projects of health
players.
•
Through a different and unconventional
view, hitt generates relevant and timely
information for both public entities and
private companies, to inform their
investment and strategic development
decisions.
•
Excellence, accountability and team efficiency
are our key performance advantages.
www.hittinnova.com
Technology life-cycle
Health Innovation Technology Transfer 3
Services
We deploy a full range of solutions to cover the main needs of knowledge of all
actors in health market.
ADVISING
PROJECTS
SUPPORT
Trusted independent advisors
for public and private health
organizations
Experts consultants on
business, investment and
clinical development strategies
High quality and broad reviews
of best state-of-the-art in
health market
www.hittinnova.com
Health Innovation Technology Transfer 4
The three pillars of development
Price
Registry
Regulatory
Health Authorities
FDA:
security & efficacy
EMA:
quality, safety & efficacy
www.hittinnova.com
Financing
Insurer
CMS:
Reasonable & Necessary
CatSalut:
appropriate adjustment
of supply to the health
needs of citizens
NHS UK:
comprehensive
range of services
Organization
Science
Finance
Start-ups often fail because
founders and investors neglect to
look before they leap, surging
forward with plans without taking
the time to realize that the base
assumption of the business plan is
wrong. They believe they can
predict the future, rather than try
to create a future with their
customers. Entrepreneurs tend to
be single-minded with their
strategies—wanting the venture
to be all about the technology or
all about the sales, without taking
time to form a balanced plan.
And all too often, they do not give
themselves wiggle room to pivot
midstream if the initial idea
doesn't jibe with customer
demand.
Shikhar Ghosh, Senior Lecturer of
Business Administration, Harvard
Business School
Health Innovation Technology Transfer 5
The current strategy…
Idea
PoC
Regulatory
Clinical Development
Basic Science / Experts
Operations
Marketing / KOL
Commercial
www.hittinnova.com
Health Innovation Technology Transfer 6
… and the hitt approach
Primary
Research
Early
Stage
Market
Access
Market
Basic Science / Experts
Operations
Marketing / KOL
Commercial
System Overview / Designing access strategies
www.hittinnova.com
Health Innovation Technology Transfer 7
Focus on
We design easier and more profitable ways for:
•
To build and consolidate strategic decisions in market access for health products & services
•
To support start-ups on their business strategy &development
•
To generate primary research in health services
Primary
Research
www.hittinnova.com
Early
Stage
Market
Access
Market
Health Innovation Technology Transfer 8
Providing key data
• Review of literature
Primary
Research
• Develop a business strategy & implement business ‘thinking’
• Landscape analysis & define relevant outcomes
• Feasibility studies (cost / operational / clinical)
• Cost-Effectiveness & Budget impact analysis (Economic
Evaluation)
• Impacts on the organizations & on clinical management
• Analyse alternatives / comparators
• Propose pricing scenarios
www.hittinnova.com
Health Innovation Technology Transfer 9
Opening new paths to success
• design and implement roadmap
Early
Stage
• validate research proposals
• validate expected outcomes
• assess business value
• refine value proposition
• early stage investing strategy
• design and implement clinical trials
www.hittinnova.com
Health Innovation Technology Transfer 10
Designing business strategies
Market
Access
•
Analyse & propose possible pricing scenarios & strategies
•
Recommend (and elaborate) value dossier content, and
incorporate HTA perspective
•
Probe intangible value
•
Economic evaluation of research findings
•
Validate expectations of Return on Investment: inform on potential
risks and mitigate and arise threats
•
Development phase projects:
•
•
•
www.hittinnova.com
Definition of most relevant outcomes
Research & economic evaluation trials
Facilitate appropriate development of PoC and Research Trials: Sites, KOL.
Health Innovation Technology Transfer 11
Projects
• hitt develops projects for top pharma companies, start-ups, government agencies
and consultancy firms in health industry.
• Some of our clients are:
Alcon · Novartis · Biomarin · BiogenIdec · ALKAbelló · Bayer · Shire ·
Astellas · Otsuka · Astra Zeneca · Hartmann · Reig Jofre · Oryzon Genomics ·
Oliver Wymann · Quintiles · Ernst&Young · Deloitte · Ernest&Young ·
Simon Kutcher & Partners · Antares Consulting · UBC ·
IMS · Ysios Capital · Proa Capital
www.hittinnova.com
Health Innovation Technology Transfer 12
How we work?
• Independent and small dynamic team, knowledgeable of both the EU and US
environments
• Alliances with the best-of-breed providers.
• Incorporating ad-hoc specialists to achieve best available expertise on a
timely and high quality manner
• Based on a network of free-standing senior international collaborators, who
have been or are in strategic decision positions mainly in the EU.
• Two stage approach
• We shall inform our clients in less than 2 weeks on the foreseen outcome of
the project, allowing them to reshape objectives
www.hittinnova.com
Health Innovation Technology Transfer 13
[email protected]
c/Avenir, 1
08006 Barcelona
T. +34 650 161 197
[email protected]
www.hittinnova.com